Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Atrium Therapeutics, Inc. (RNA)

8.27 +0.01 (+0.12%)
At close: October 30 at 4:00:00 PM EDT
Trade RNA on Coinbase
Chart Range Bar
Loading chart for RNA
  • Previous Close 8.26
  • Open 8.19
  • Bid 5.96 x 200
  • Ask 10.09 x 200
  • Day's Range 7.88 - 8.31
  • 52 Week Range 7.49 - 16.77
  • Volume 566,643
  • Avg. Volume 279,135
  • Market Cap (intraday) 141.464M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -5.44
  • Earnings Date (est.) Nov 9, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 22.00
  • Zacks Rating Bullish

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.

atriumtherapeutics.com

--

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

RNA
43.28%
S&P 500 (^GSPC)
10.73%

1-Year Return

RNA
43.28%
S&P 500 (^GSPC)
11.11%

3-Year Return

RNA
43.28%
S&P 500 (^GSPC)
81.91%

5-Year Return

RNA
43.28%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 3M
Earnings -20.19M
Profit Margin -671.97%

Q1

FY26

Q2

FY26

-20M
-10M
0
10M
-600.0%
-400.0%
-200.0%

Analyst Insights

View More

Analyst Price Targets

15.00
22.00 Average
8.27 Current
25.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/28/2026
Analyst HC Wainwright & Co.
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 25 -> 20

Statistics

View More

Valuation Measures

Annual
As of 10/30/2026
  • Market Cap

    142.15M

  • Enterprise Value

    -120.07M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    3.97

  • Price/Book (mrq)

    0.66

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -184.15%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    35.84M

  • Net Income Avi to Common (ttm)

    -65.99M

  • Diluted EPS (ttm)

    -5.44

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    263.9M

  • Total Debt/Equity (mrq)

    0.78%

  • Levered Free Cash Flow (ttm)

    --

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

8.27 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: